Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Evaluation of Soluble Human Leukocyte Antigen-G (sHLA-G) Isoforms and Regulatory T Cells in Relapsing-Remitting Multiple Sclerosis.
Butyrate, neuroepigenetics and the gut microbiome: Can a high fiber diet improve brain health?
Charcot-marie-tooth disease type 1x in women: Electrodiagnostic findings.
Sphingosine-1-phosphate receptor inhibition prevents denervation-induced dendritic atrophy.
The protective effects of bioactive (RS)-glucoraphanin on the permeability of the mice blood-brain barrier following experimental autoimmune encephalomyelitis.
Adaptive personalized training games for individual and collaborative rehabilitation of people with multiple sclerosis.
Optimal design of clinical trials with biologics using dose-time-response models.
The Primate EAE Model Points at EBV-Infected B Cells as a Preferential Therapy Target in Multiple Sclerosis.
Variability in intravenous immunoglobulin G regimens for autoimmune neuromuscular disorders.
Possible second motor neuron damage in neuromyelitis optica.
Clinical features of patients with Guillain-Barré syndrome at seven hospitals on the East Coast of Australia.
Multiple sclerosis: CCSVI deconstructed and discarded.
Is it time to revise the classification of geographical distribution of multiple sclerosis?
Disease mechanisms in MS: Cell adhesion molecule MCAM on pathogenic T cells-a green light for CNS entry in multiple sclerosis.
Polyarteritis nodosa with central nervous system involvement mimicking relapsing-remitting multiple sclerosis.
[The effect of tobacco smoking on clinical effectiveness of immunomodulatory treatment in multiple sclerosis patients].
Neural drive increases following resistance training in patients with multiple sclerosis.
Register-based incidence of multiple sclerosis in Brittany (north-western France), 2000-2001.
Mesenchymal stem cells: A new diagnostic tool?
A critical period for social experience-dependent oligodendrocyte maturation and myelination.
Quantitative PCR Analysis of DNA Aptamer Pharmacokinetics in Mice.
[Pay attention to the differences and similarities in the pathogenesis and management of multiple sclerosis and neuromyelitis optica].
Multiple sclerosis: Grey matter atrophy in the thoracic spinal cord is associated with disability in patients with multiple sclerosis.
Explaining, not just predicting, drives interest in personal genomics.
Brainstem and limbic encephalitis with paraneoplastic neuromyelitis optica.
Pages
« first
‹ previous
…
507
508
509
510
511
512
513
514
515
…
next ›
last »